Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015. 2017

Marcello Moccia, and Raffaele Palladino, and Roberta Lanzillo, and Antonio Carotenuto, and Cinzia Valeria Russo, and Maria Triassi, and Vincenzo Brescia Morra
Multiple Sclerosis Clinical Care and Research Centre, Department of Neurosciences, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy.

BACKGROUND Disease modifying treatments (DMTs) are the main responsible for direct medical costs in multiple sclerosis (MS). The current investigation aims at evaluating possible associations between healthcare costs for treating relapsing remitting MS (RRMS) and disease evolution. METHODS The present cohort study retrospectively included 544 newly diagnosed RRMS patients, prospectively followed up for 10.1±3.3 years. Costs for DMT administration and management were calculated for each year of observation. Following clinical endpoints were recorded: time to first relapse, 1-point EDSS progression, reaching of EDSS 4.0, reaching of EDSS 6.0, and conversion to secondary progressive MS (SP). Covariates for statistical analyses were age, gender, disease duration and EDSS at diagnosis. RESULTS At time varying Cox regression models, 10% increase in annual healthcare costs was associated with 1.1% reduction in 1-point EDSS progression (HR = 0.897; p = 0.018), with 0.7% reduction in reaching EDSS 6.0 (HR = 0.925; p = 0.030), and with 1.0% reduction in SP conversion (HR = 0.902; p = 0.006). CONCLUSIONS Higher healthcare costs for treating MS have been associated with a milder disease evolution after 10 years, with possible reduction of long-term non-medical direct and indirect costs.

UI MeSH Term Description Entries
D008297 Male Males
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D017048 Health Care Costs The actual costs of providing services related to the delivery of health care, including the costs of procedures, therapies, and medications. It is differentiated from HEALTH EXPENDITURES, which refers to the amount of money paid for the services, and from fees, which refers to the amount charged, regardless of cost. Medical Care Costs,Treatment Costs,Costs, Medical Care,Health Costs,Healthcare Costs,Cost, Health,Cost, Health Care,Cost, Healthcare,Cost, Medical Care,Cost, Treatment,Costs, Health,Costs, Health Care,Costs, Healthcare,Costs, Treatment,Health Care Cost,Health Cost,Healthcare Cost,Medical Care Cost,Treatment Cost
D053208 Kaplan-Meier Estimate A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995) Kaplan-Meier Survival Curve,Kaplan-Meier Analysis,Kaplan-Meier Survival Curves,Kaplan-Meier Test,Product-Limit Method,Analysis, Kaplan-Meier,Curve, Kaplan-Meier Survival,Curves, Kaplan-Meier Survival,Estimate, Kaplan-Meier,Kaplan Meier Analysis,Kaplan Meier Survival Curve,Kaplan Meier Survival Curves,Kaplan Meier Test,Method, Product-Limit,Methods, Product-Limit,Product Limit Method,Product-Limit Methods,Survival Curve, Kaplan-Meier,Survival Curves, Kaplan-Meier,Test, Kaplan-Meier

Related Publications

Marcello Moccia, and Raffaele Palladino, and Roberta Lanzillo, and Antonio Carotenuto, and Cinzia Valeria Russo, and Maria Triassi, and Vincenzo Brescia Morra
January 2018, PloS one,
Marcello Moccia, and Raffaele Palladino, and Roberta Lanzillo, and Antonio Carotenuto, and Cinzia Valeria Russo, and Maria Triassi, and Vincenzo Brescia Morra
March 2016, European journal of neurology,
Marcello Moccia, and Raffaele Palladino, and Roberta Lanzillo, and Antonio Carotenuto, and Cinzia Valeria Russo, and Maria Triassi, and Vincenzo Brescia Morra
April 2024, Journal of clinical nursing,
Marcello Moccia, and Raffaele Palladino, and Roberta Lanzillo, and Antonio Carotenuto, and Cinzia Valeria Russo, and Maria Triassi, and Vincenzo Brescia Morra
January 2020, European neurology,
Marcello Moccia, and Raffaele Palladino, and Roberta Lanzillo, and Antonio Carotenuto, and Cinzia Valeria Russo, and Maria Triassi, and Vincenzo Brescia Morra
January 2019, Frontiers in neurology,
Marcello Moccia, and Raffaele Palladino, and Roberta Lanzillo, and Antonio Carotenuto, and Cinzia Valeria Russo, and Maria Triassi, and Vincenzo Brescia Morra
January 2015, Expert opinion on drug safety,
Marcello Moccia, and Raffaele Palladino, and Roberta Lanzillo, and Antonio Carotenuto, and Cinzia Valeria Russo, and Maria Triassi, and Vincenzo Brescia Morra
November 2004, Journal of evaluation in clinical practice,
Marcello Moccia, and Raffaele Palladino, and Roberta Lanzillo, and Antonio Carotenuto, and Cinzia Valeria Russo, and Maria Triassi, and Vincenzo Brescia Morra
May 2011, European journal of cancer care,
Marcello Moccia, and Raffaele Palladino, and Roberta Lanzillo, and Antonio Carotenuto, and Cinzia Valeria Russo, and Maria Triassi, and Vincenzo Brescia Morra
December 2019, The Lancet. Neurology,
Marcello Moccia, and Raffaele Palladino, and Roberta Lanzillo, and Antonio Carotenuto, and Cinzia Valeria Russo, and Maria Triassi, and Vincenzo Brescia Morra
February 2018, Multiple sclerosis (Houndmills, Basingstoke, England),
Copied contents to your clipboard!